Press Releases
2024
EpicentRx’s Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment
LA JOLLA, California, December 5, 2024 — EpicentRx announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the oncolytic adenovirus-delivered transforming growth factor beta (TGFβ) inhibitor, AdAPT-001, plus the anti-PD-1,...
EpicentRx To Present Compelling Phase 2 Clinical Data on AdAPT-001 Plus a Checkpoint Inhibitor in PD-1/L1 Resistant Tumors at the SITC 39th Annual Meeting
The combination AdAPT-001 + a checkpoint inhibitor achieved high durable overall response rates and an 8 month+ PFS in patients who progressed on checkpoint inhibitors and chemotherapy TORREY PINES, Calif., Oct. 28, 2024 – EpicentRx, a clinical-stage biopharmaceutical...
EpicentRx Selected for Oral Nanosymposium Session on Anti-ALS/MND Activity of RRx-001 at the 2024 Society for Neuroscience (SfN) Meeting
San Diego, October 2, 2024 – EpicentRx today announce its lead small molecule, RRx-001 (nibrozetone), is the subject of an oral nanosymposium session in amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) at the 2024 Society for Neuroscience (SfN) during...
RRx-001 To Be Featured at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
San Diego, Sept.30, 2024 – EpicentRx, a clinical stage biopharmaceutical company with strong momentum and big plans, will present compelling preclinical data on lead small molecule, RRx-001 (nibrozetone), in Parkinson’s Disease (PD) at the 2024 International Congress...
EpicentRx Receives Highly Competitive US Department of Defense (DoD) Translational Award to Develop RRx-001 as a Neuroprotective Medical Countermeasure
The highly competitive award from the CDMRP Toxic Exposures Research Program will fund the development of EpicentRx’s small molecule, RRx-001 (nibrozetone), as a neuroprotective agent and medical countermeasure against neurotoxic chemical exposures. TORREY PINES, CA,...
EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
Data affirm positive immune effects of AdAPT-001 plus a checkpoint inhibitor in sarcomas and triple negative breast cancer with established checkpoint-inhibitor resistance The paucity of immune related adverse events suggests that AdAPT-001 may protect against them...
EpicentRx to Present Positive Phase 2a Clinical Data with its AdAPT-001 TGF-β Trap Program in Checkpoint Inhibitor Resistant Patients at the 2024 AACR Meeting
Compelling clinical data demonstrate that AdAPT-001, which delivers a TGF-β trap to tumors, reverses established resistance to checkpoint inhibitors and makes checkpoint inhibitors more active SAN DIEGO, April 2, 2024 /PRNewswire/ -- EpicentRx, Inc, a clinical-stage...
2023
EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson’s Disease and ALS/MND at Neuroscience 2023
TORREY PINES, Calif., Nov. 6, 2023 /PRNewswire/ -- EpicentRx, Inc. ("EpicentRx"), a clinical-stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, has been selected for oral and poster presentations at the...
United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recognizes New Therapeutic Class by Granting “nibrozetone” as New Generic Name for EpicentRx’s Lead Small Molecule NLRP3 Inhibitor, RRx-001
New USAN name, a shortening of its chemical name, signifies a novel therapeutic class Novel generic name highlights the anti-inflammatory, anticancer, and antioxidant properties of RRx-001 and its potential to address several diverse unmet therapeutic needs TORREY...
EpicentRx Presents Updates on its Oncology Clinical Development Programs at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Company details follow-on Phase 2b study design in head and neck cancer for its lead small molecule candidate, RRx-001 Company also presented positive first-in-human data from its TGF-β trap vector, AdAPT-001 TORREY PINES, Calif., June 2, 2023 /PRNewswire/ --...
EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001, to Prevent/Attenuate Chemotherapy and Radiation Treatment Induced Severe Oral Mucositis
FDA also accepts company's Investigational New Drug (IND) application to initiate a follow-on phase 2b clinical trial, called KEVLARx TORREY PINES, CA, March 29, 2023 — EpicentRx, Inc. (“EpicentRx”), announced today that the U.S. Food and Drug Administration (FDA)...
EpicentRx To Present at International Symposium on the Neuroprotective Effects of RRx-001 in Alzheimer’s and Parkinson’s diseases in Multiple Disease Models
TORREY PINES, Calif., March 28, 2023 -- EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company, has been selected for a symposium presentation at AD/PD 2023, an International Conference on Alzheimer’s & Parkinson’s Diseases taking...
Review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs
RRx-001 is a small molecule direct NLRP3 inflammasome inhibitor with activity in cancer, neurodegeneration, and other inflammatory conditions RRx-001 is the most advanced direct NLRP3 inflammasome inhibitor in clinical development, having been evaluated in over 300...
Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors
The combination of RRx-001 + Opdivo was well tolerated PRIMETIME was a small, duration-limited pilot study with an encouraging but preliminary anticancer signal in cold, non-immunogenic tumors TORREY PINES, Calif., March 15, 2023 /PRNewswire/ -- EpicentRx, a leading...
EpicentRx Presents Poster on the Nephroprotective Effects of RRx-001 in Patients with Solid Tumors that Receive Cisplatin/Etoposide at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
TORREY PINES, Calif., February 15, 2023 -- EpicentRx, Inc. (“EpicentRx”), a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced that it has been selected for a poster...
EpicentRx Announces Presentation for Phase 2 Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third/Fourth Line Colorectal Cancer at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Torrey Pines, Calif., January 20, 2023 - EpicentRx, Inc, a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, today announced data from a Phase 2 randomized clinical trial of...
EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers
Results from PREVLAR trial Demonstrate RRx-001 protects against severe oral mucositis or blistering from radiation in first line head and neck cancer Study published in International Journal of Radiation Oncology, Biology and Physics, also known as The Red Journal...
2022
RRx-001 + Irinotecan Significantly Improved Progression Free Survival (PFS) Versus Regorafenib in the Randomized Phase 2 ROCKET Trial in Advanced Colorectal Cancer
Results from the ROCKET trial, published in the journal Clinical Colorectal Cancer, demonstrate the potential chemoprotective effects of RRx-001 San Diego, Calif., Dec. 14, 2022 - EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical company...
EpicentRx Announces Patent Issued for Radiation Protection with RRx-001 in Combination Regimens
Dual anti-cancer and radio/chemoprotective agent reduces toxicity from radiation exposure Torrey Pines, Calif., December 6, 2022 - EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical company that uses groundbreaking science to treat cancer...
EpicentRx Awarded Funding from FightMND to Evaluate Therapeutic Potential of RRx-001 in Motor Neuron Disease (aka ALS)
The funding will support study of lead small molecule inflammasome inhibitor in MND, also known as amyotrophic lateral sclerosis (ALS) Torrey Pines, Calif. and Queensland, Australia, Nov. 29, 2022 /PRNewswire/ - EpicentRx Inc. ("EpicentRx"), a late-stage...
EpicentRx Announces Presentations Focusing on RRx-001 Inhibition of the NLRP3 Inflammasome at Two Upcoming Scientific Conferences
Presentations at Neuroscience 2022 and the 4th Inflammasome Therapeutics Summit will highlight the potential for RRx-001 to prevent and treat a broad range of chronic diseases Torrey Pines, Calif., November 10, 2022 – EpicentRx, a late clinical stage biopharmaceutical...
EpicentRx Announces First Patient Dosed in China for the Phase 3 REPLATINUM Global Study with RRx-001 in Third Line and Beyond Extensive Stage Small Cell Lung Cancer (SCLC)
License partner SciClone Pharmaceuticals oversees trial in China. Phase 3 REPLATINUM multicenter clinical trial with over 50 sites in the U.S. and China is underway Torrey Pines, Calif., Oct. 6, 2022 /PRNewswire/ - EpicentRx, a late clinical stage biopharmaceutical...
EpicentRx Publishes Commentary in International Journal of Infectious Disease (IJID) on Need for a “Universal” Coronavirus Vaccine to be More Effective Against Novel Viral Variants
Commentary points to need for a vaccine based on nucleocapsid vs. spike protein to make vaccine less vulnerable to mutation and provide stronger immunity to novel viral variants Company’s development of a nucleocapsid vaccine, a recombinant replication-competent...
New industry partnership to accelerate development of Parkinson’s disease treatments
BRISBANE, AUSTRALIA, July 12, 2022 – University of Queensland researchers will partner with American biopharmaceutical company EpicentRx Inc. to evaluate new treatments for Parkinson’s disease (PD), speeding up development of potential new therapies. UQ and EpicentRx...
EpicentRx Awarded Grant from The Michael J. Fox Foundation to Evaluate Therapeutic Potential of RRx-001 in Parkinson’s Disease
The $500,000 USD grant will support study of EpicentRx’s lead small molecule inflammasome inhibitor TORREY PINES, Calif., July 12, 2022 -- EpicentRx Inc. (“EpicentRx”), a late-stage biopharmaceutical company developing platforms that treat and target multiple...
EpicentRx Announces Poster Presentation for Phase 2 Randomized Clinical Trial with RRx-001 as an Anti-Mucositis Agent in Locally Advanced Head and Neck Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
TORREY PINES, Calif., June 1, 2022 -- EpicentRx, Inc, a privately-held clinical-stage biotechnology company at the forefront of developing oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that...
EpicentRx Announces Oral and Poster Presentations at the 2022 American Thoracic Society (ATS) Respiratory Innovation Summit
TORREY PINES, Calif., May 10, 2022 -- EpicentRx, Inc., a privately-held clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that it has been...
EpicentRx “BETA-PRIME” Phase 1 Study Progresses After Demonstrating Good Safety and Tolerability
Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer TORREY PINES, Calif., April 21, 2022 -- EpicentRx Inc., a leading-edge immunotherapy company using...
EpicentRx and Texas Children’s Cancer Center Announce the Initiation of a Phase 1 Clinical Trial with RRx-001 for Pediatric CNS Tumors
TORREY PINES, Calif., Feb. 23, 2022 – EpicentRx, Inc., a clinical stage drug and device company, in collaboration with the Texas Children's Cancer Center in Houston, today announced the start of a Phase 1 study to examine the safety and benefit of its lead small...
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy
Collaboration builds on recent data presented by Actinium at SITC demonstrating enhanced activity of targeted radiotherapies in combination with the anti-CD47 targeting antibody magrolimab in blood cancer and solid tumor models Collaboration to explore Actinium’s...
2021
EpicentRx Publishes Proof-of-Concept Research on AdAPT-001
Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap La Jolla, Calif., Dec. 8, 2021 - EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...
EpicentRx Granted New Composition of Matter Patent for Its TGF-ß Trap Fusion Protein
La Jolla, Calif., Nov. 22, 2021 - EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and...
EpicentRx Announces Publication of Phase 1 Trial Results for the Anti-Cancer Agent, RRx-001, in Lancet Oncology
MOUNTAIN VIEW, Calif., August 19, 2015 -- EpicentRx, Inc., a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of potent, novel anti-cancer agents, announced today the publication of positive results...
EpicentRx Announces Completion of First Cohort in Phase 1 “BETA PRIME” Trial with AdAPT-001
Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer Torrey Pines, Calif., Sept. 29, 2021- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today announced...
EpicentRx, Inc. in an Expansive Growth Phase
Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...
2020
EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China
SciClone granted exclusive license to co-develop and commercialize RRx-001 upon approval in the Greater China Region LA JOLLA, Calif., July 1, 2020 -- EpicentRx Inc. ("EpicentRx"), a San Diego-based clinical cancer immunotherapy company and SciClone Pharmaceuticals...
EpicentRx Appoints Life Sciences Investment Banking Veteran, Dr. Franck Brinkhaus, as President and Chief Financial Officer
TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...
EpicentRx Appoints Oncologist Tony Reid, M.D., Ph.D., as Chief Executive Officer (CEO)
TORREY PINES, Calif., May 29, 2020 -- EpicentRx, a next-generation clinical immuno-oncology company, today announced the appointment of physician, scientist and businessman Tony Reid, M.D., Ph.D., as the company's chief executive officer. Dr. Reid who is a co-founder...
EpicentRx IND Application for Second Immuno-oncology Program, a TGF-β Trap Adenovirus, Receives FDA Clearance
EpicentRx’s lead program is the first-in-class small molecule CD47 antagonist RRx-001 in Phase 3 for small cell lung cancer Enrollment of Phase I trial for adenovirus program AIM-001 expected to begin this year Close of recent $35M series D will advance AIM-001 and...
2019
EpicentRx Appoints Senior Life Science Financial Executive Dr. Franck Brinkhaus as Chief Financial Officer
TORREY PINES, Calif., June 10, 2020 -- EpicentRx, Inc., a clinical-stage pharmaceutical company on a mission to advance its portfolio of small molecule and virus-based immunotherapies for the treatment of patients with cancer and other diseases of high unmet need such...
EpicentRx Announces Positive Results From Phase 1 Trial of RRx-001 as First-line Treatment in Newly Diagnosed Glioblastoma
RRx-001 led to an overall survival of 21.9 months and progression-free survival of 13 months Data presented at the Society for Neuro-Oncology annual meeting LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune...
EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform
Series D Funded by an undisclosed source from Europe Total capital raised by EpicentRx approximately $77 million LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with...
EpicentRx Initiates Dosing in Phase 3 Trial of Immunotherapy RRx-001 for Third-line Small Cell Lung Cancer
LA JOLLA, Calif. -- EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has dosed the first patient in the Phase 3 REPLATINUM trial evaluating...
EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)
LA JOLLA, Calif., June 25, 2019 -- EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate both innate and adaptive anticancer responses, today announced the publication of positive results from its Phase 2 clinical...
2018 & Prior
EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines
SAN DIEGO, May 2, 2018 -- EpicentRx, a San Diego biotechnology company developing a next-generation immunotherapy platform of viruses that infect and kill cancer cells for the treatment of several tumor types, has developed the first ever series of oncolytic viruses...
Media
Outside the box
Age Old Question
Published in the November edition of PharmaTimes – We’re all getting older but what can we do to halt its wicked ways? Old age. It’s something we all have in common. We either are old or, with a certain amount of fortune, we will experience it at some stage in the future. But with old age, comes trepidation.
Endometriosis: An immune disease
Published in Drug Discovery & Development – Endometriosis is a chronic incurable gynecological condition with cyclical pelvic pain, heavy bleeding, infertility, and reduced quality of life as its main manifestations. Almost half of women with it experience infertility. [1] No symptoms are specifically pathognomonic or characteristic of endometriosis. Often referred to as a ‘silent disease’ because of how often the diagnosis is missed, delayed, or dismissed, the rapid upward incidence of endometriosis since the 1980s has also led to the use of the term “silent epidemic”. [2] Approximately 10 percent of reproductive age women, or 190 million globally are impacted by it, which is no small number.
Bizzaro Cancer World
VJ Oncology
YouTube video interviews with Dr. Lucy Kennedy from Cleveland Clinic Development of AdAPT-001, a novel TGF-β-trap-enhanced oncolytic virus Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors The future of AdAPT-001 in patients...
Targeted Oncology
Why Personalized Medicine Should Not Be Too Personalized
A licence to kill
Predicting the Abscopal Phenomenon – Letter to the Editor
Dr Tony Reid Of EpicentRx: 5 Things I Wish Someone Told Me When I First Became A Doctor
Bug in the system
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors
Age of posterity: Anti-inflammaging – a very modern dichotomy
Commentary on oncolytic viruses: past, present, and future
Tutorial on Data Management
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Partnering with EpicentRx
“You are only as good as the company you keep” also applies to therapeutics like AdAPT-001 – EpicentRx
Severe Oral Mucositis: Companies Put Their Money where the Mouth is and Vie for a Marketshare
A View to a Kill: Are viruses alive or dead and is it time to find out?
AdAPT-001 Mechanism of Action
AdAPT-001 doesn’t just create a cancer-targeted infection, it produces a proprietary TGFβ “trap”...
Conferences
AHA (American Heart Association) Scientific Sessions 2022
November 5-7 , 2022 – McCormick Place, Chicago, IL
View Poster
American Society of Clinical Oncology (ASCO)
May 31-June 4, 2024 – Chicago, Illinois
Oral Presentation: Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.
Learn more
American Physiology Summitt
April 2024 – Long Beach, California
Learn more
American Association for Cancer Research (AACR)
April 2024 – San Diego, California
Poster Session: Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +/- a checkpoint inhibitor
Learn more
Precision Medicine World Conference
January 2024; Silicon Valley, California
Oral Presentation: AdAPT-001 in Advanced Soft-Tissue Sarcoma (BETA PRIME)
Learn more
Oncolytic Virotherapy Summit 2023
December 2023; Boston, MA
Oral Presentation: Evaluating the Advantages & Hurdles of Intratumoral Delivery of Oncolytic Viruses
Inflammasome Therapeutics Summit
November 2023; Boston, Massachusetts
Oral Presentation: The Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases
Neuroscience 2023
November 2023; Washington D.C.
Oral Presentation: The CNS-permeable NLRP3 inhibitor RRx-001 is neuroprotective in experimental models of Parkinson’s disease
American Society of Clinical Oncology (ASCO) Annual Meeting 2023
June 2023; Chicago, Illinois
Poster: RRX-001 Initial results from a first in human dose escalation trial of a novel immune stimulating oncolytic adenovirus, AdAPT-001 TGF-ß Trap (NCT04673942)
Poster: RRX-001, KEVLARx: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. SOC in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC).
AD/PD 2023 (Alzheimer’s & Parkinson’s Diseases International Conference)
March 2023, Gothenburg Sweden
Oral Presentation: RRx-001, A Direct NLRP3 Inhibitor and Phase 3 Small Molecule Improves Alzheimer’s and Parkinson’s Pathology in Multiple Disease Models
SITC 2023 Spring Scientific
March 2023, Denver Colorado
Poster: TRIAL-IN-PROGRESS BETA-PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors (NCT04673942)
Poster: Low dose but not high dose RRx-001 repolarizes tumor associated macrophages from an M2 to M1 phenotype in colorectal cancer
American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
February 2023, San Francisco, California
Poster: Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors
3rd TGF-B for Immuno-Oncology Drug Development Summit 2023
January 2023, San Francisco, California
Oral Presentation: Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001
- Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001
- Using correlative studies for measuring expression in the clinic
- Discussing neutralizing TGF-β for improving checkpoint inhibitors
American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2023
January 2023, San Francisco, California
Poster: Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.
San Antonio Breast Cancer Summit (SABCS) 2022
December 2022, San Antonio, Texas
Poster: Treatment of 4T1 Breast Cancer with Liposome-Encapsulated AdAPT-001, a TGF-beta Trap Encoded Oncolytic Adenovirus Currently in a Phase 1/2 Anticancer Trial
4th Inflammasome Therapeutics Summit 2022
November 2022, Boston, Massachusetts
Oral Presentation: RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases
- Evaluate strategy and execution of drug design and translational development
- Understanding relevant pathology of disease and most up to date learnings on the inflammasome mechanisms, drug design, and patient population
- Exploring the latest data, potential biomarkers, challenges, and future directions
Neuroscience 2022 Conference – Society for Neuroscience
November 2022, San Diego, California
Oral Presentation: The NLRP3 inhibitor RRx-001 crosses the blood brain barrier and alleviates neuroinflammation in experimental models of Parkinson’s disease
Alzheimer’s Association International Conference (AAIC) 2022
July 2022, San Diego, California
Poster: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice
2022 Scientific Sessions of the National Lipid Association (NLA)
June 2022, San Francisco, California
Poster: The NLRP3 inhibitor and Nrf2 agonist, RRx-001, ameliorates non-alcoholic fatty liver disease (NAFLD/NASH) in rats
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022, Chicago, Illinois
Poster: Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in head and neck cancer patients treated with chemoradiation (PREVLAR)
American Thoracic Society (ATS) Respiratory Innovation Summit
May 2022, San Francisco, California
Oral Presentation: Inflammation and Immunology: Feature Company Showcase
Poster: The ABCs of COVID-19 Related ARDS Treatment
Poster: N-VAX, a universal coronavirus vaccine
Poster: RRx-001, an NLRP3 inflammasome inhibitor, ameliorates bleomycin-induced pulmonary fibrosis
World Vaccine & Immunotherapy, World Antiviral Congress 2021
November 2021, San Diego, California
Oral Presentation: AdAPT-001, an oncolytic adenovirus armed with a TGF-beta “trap” fusion protein
EMBO Workshop “The inflammasomes: The next frontier” 2021
September 2021, Martinsried, Germany
Abstract: The direct NLRP3 inhibitor and Phase 3 anticancer agent, RRx-001, ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice
TGFβ for Immuno-Oncology Drug Development Conference 2021
January 2021, Virtual
Poster: AdAPT-001, a replication competent type 5 adenovirus carrying a TGF-β “trap”, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
American Society for Radiation Oncology (ASTRO) 2020
October 2020, Virtual
Oral Presentation: Results of a Randomized, Open Label, Multicenter Trial Assessing the Safety, Dose and Schedule of RRx-001 (R001) in Reducing Severe Oral Mucositis (SOM) in Patients Receiving Chemoradiation (CRT) for Oral Cavity/oropharynx Squamous Cell Carcinoma (OSCC)
American Society of Clinical Oncology (ASCO) Annual Meeting 2020
June 2020, Virtual
Poster: Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule of RRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced.
Abstract: Phase 2 Expansion Cohort in Colorectal Cancer to Evaluate the Safety and Tolerability of RRx-001 Blood Mix.
Abstract: Phase 1 Pilot Study of RRx-001 + Nivolumab in Patients with Traditionally Non-Checkpoint Inhibitor-Responsive Cancers (PRIMETIME).
Abstract: DCE-MRI Evaluation of Ten Patients with Brain Metastases Treated with RRx-001, a CD47 and PD-L1 Downregulator, in a Phase 1/2 Trial Called BRAINSTORM.
Abstract: A phase 3 trial-in-progress called REPLATINUM that compares RRx-001 + a platinum doublet to a platinum doublet in third-line or beyond small cell lung cancer.
Abstract: Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial.
Abstract: Phase 1 Study (PAYLOAD) of RRx-001 + Irinotecan in Patients with Advanced Solid Malignancies.
American Association for Cancer Research (AACR) Annual Meeting 2019
March 2019, Atlanta, Georgia
Abstract: Response to RRx-001 in SCLC is positively correlated with a reduction in CD206(+) HLA-DR(-/low) myeloid-derived suppressor cells
Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018
November 2018, Washington, D.C.
Abstract: BETATRAP, a replication competent type 5 adenovirus carrying a TGF-beta trap, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model
Society for Neuro-Oncology (SNO) 2018
November 2018, New Orleans, Louisiana
Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase 1 dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
American Society for Radiation Oncology (ASTRO) 2018
October 2018, San Antonio, Texas
Abstract: Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
American Society of Clinical Oncology (ASCO) Annual Meeting 2018
June 2018, Chicago, Illinois
Abstract: QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer
Genitourinary Cancers Symposium 2018
February 2018, San Francisco, California
Abstract: Sensitization of neuroendocrine prostate cancer by RRx-001
ASCO-SITC Clinical Immuno-Oncology Symposium 2018 February 2018, Virtual
February 2018, Virtual
Abstract: RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment
Radiation Research Society (RRS) Annual Meeting 2017
October 2017, Cancun, Mexico
Abstract: Radioprotective effects of RRx-001 on the pathophysiology of the hematopoietic system using a murine radiation model
American Association for Cancer Research (AACR) Annual Meeting 2017
April 2017, Washington, DC.
Abstract: The immunomodulatory anticancer agent RRx-001 induces a vaccine-like interferon response through epigenetic induction of viral mimicry
Abstract: Epigenetic and biological effects of 5-azacytidine and RRX-001 on DLD-1 colorectal cancer cell lines
Abstract: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF-β pathway activation and markers for fibrosis
American Association for Cancer Research (AACR) Annual Meeting 2016
April 2016, New Orleans, Louisiana
Abstract: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001
Abstract: RRx-001 is effective in temozolomide-sensitive and resistant GBM
Abstract: Improved statistical approaches that account for pseudoprogression in preclinical studies of RRx-001 with immunotherapies
American Society of Hematology (ASH) 2015
December 2015, Orlando, Florida
Oral Presentation: The hypoxia-selective epigenetic agent, RRx-001, triggers apoptosis and overcomes drug-resistance in multiple myeloma cells
AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2015
November 2015, Boston, Massachusetts
Abstract: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model
Stem Cells Regenerative Medicine Congress 2015
September 2015, Washington, D.C.
Invited Presentation: Restoring efficacy of immunotherapy treatments in oncology with radical oxygen and nitrogen based epigenetic drugs
AACR, Chromatin and Epigenetics in Cancer 2015
September 2015, Atlanta, Georgia
Abstract: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing Phase 2 colorectal cancer study, “ROCKET”
International Society for Magnetic Resonance in Medicine (ISMRM) 2015
May 2015, Toronto, Canada
Abstract: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
American Association for Cancer Research (AACR) Annual Meeting 2015
April 2015, Philadelphia, Pennsylvania
Abstract: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
13th International Congress on Targeted Anticancer Therapies (TAT) 2015
March 2015, Paris, France
Abstract: Early results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor, resensitization to irinotecan in colorectal cancer
Clinical Epigenetics International Meeting (CLEPSO) 2015
March 2015, Düsseldorf, Germany
Abstract: Early results from a phase 2 study of RRx-001, a novel epigenetic modulator, show resensitization to irinotecan in colorectal cancer
4th International Workshop on Nitric Oxide in Cancer Therapy 2015
March 2015, Seville, Spain
Invited Presentation: Early results from a phase 2 study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer
AACR Translation of the Cancer Genome Conference 2015
February 2015, San Francisco, California
Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study
17th Annual Symposium on Anti-Angiogenesis and Immune Therapies 2015
Feb 2015, La Jolla, California
Abstract: RRx-001, a novel first in class epigenetic modulator, ‘episensitizes’ colorectal patients to FOLFIRI: Preliminary resensitization data from the phase 2 “ROCKET” study
International Society For Extracellular Vesicles (ISEV) 2014
October 2014, San Diego, California
Abstract: RRx-001 an EXO-based epigenetic anti-cancer agent in phase 2 clinical trials
American Association for Cancer Research (AACR) Annual Meeting 2014
Apr 2014, San Diego, California
Abstract: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice
Abstract: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase
Abstract: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI in preclinical tumor models
16th International Symposium on Anti-Angiogenic Therapy 2014
February 2014, La Jolla, California
Abstract: Resensitization to previous chemotherapy with the novel hypomethylating anticancer agent RRx-001
The recent backdrop of the very polarizing US Presidential election serves as the central analogy for an EpicentRx-authored article about macrophages in the December edition of PharmaTimes. Read more here and cast your vote on this well-written article entitled “Outside the Box”:…